Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors
- 2 October 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in The Journal of Antibiotics
- Vol. 73 (1), 5-27
- https://doi.org/10.1038/s41429-019-0240-6
Abstract
The development of new mechanisms of resistance among pathogens, the occurrence and transmission of genes responsible for antibiotic insensitivity, as well as cancer diseases have been a serious clinical problem around the world for over 50 years. Therefore, intense searching of new leading structures and active substances, which may be used as new drugs, especially against strain resistant to all available therapeutics, is very important. Dihydrofolate reductase (DHFR) has attracted a lot of attention as a molecular target for bacterial resistance over several decades, resulting in a number of useful agents. Trimethoprim (TMP), (2,4-diamino-5-(3′,4′,5′-trimethoxybenzyl)pyrimidine) is the well-known dihydrofolate reductase inhibitor and one of the standard antibiotics used in urinary tract infections (UTIs). This review highlights advances in design, synthesis, and biological evaluations in structural modifications of TMP as DHFR inhibitors. In addition, this report presents the differences in the active site of human and pathogen DHFR. Moreover, an excellent review of DHFR inhibition and their relevance to antimicrobial and parasitic chemotherapy was presented.Keywords
This publication has 176 references indexed in Scilit:
- Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised targetProceedings of the National Academy of Sciences of the United States of America, 2012
- 2,4-Diamino-5-(2′-arylpropargyl)pyrimidine derivatives as new nonclassical antifolates for human dihydrofolate reductase inhibitionJournal of Molecular Graphics and Modelling, 2011
- Predicting resistance mutations using protein design algorithmsProceedings of the National Academy of Sciences of the United States of America, 2010
- Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductaseJournal of Structural Biology, 2010
- In Vitro Bactericidal Activity of Iclaprim in Human PlasmaAntimicrobial Agents and Chemotherapy, 2009
- Design, Synthesis, and X-ray Crystal Structure of Classical and Nonclassical 2-Amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as Dual Thymidylate Synthase and Dihydrofolate Reductase Inhibitors and as Potential Antitumor AgentsJournal of Medicinal Chemistry, 2009
- Crystal Structures of Wild-type and Mutant Methicillin-resistant Staphylococcus aureus Dihydrofolate Reductase Reveal an Alternate Conformation of NADPH That May Be Linked to Trimethoprim ResistanceJournal of Molecular Biology, 2009
- Probing the Active Site ofCandida glabrataDihydrofolate Reductase with High Resolution Crystal Structures and the Synthesis of New InhibitorsChemical Biology & Drug Design, 2008
- Synthetic and Crystallographic Studies of a New Inhibitor Series Targeting Bacillus anthracis Dihydrofolate ReductaseJournal of Medicinal Chemistry, 2008
- Structure-Guided Development of Efficacious Antifungal Agents Targeting Candida glabrata Dihydrofolate ReductaseCell Chemical Biology, 2008